Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration today cautioned patients and healthcare providers against changing treatments based on results from pharmacogenetic tests with unproven indications that the agency hasn't approved for marketing.

The FDA further indicated it is looking into companies selling PGx testing for unapproved uses and may take compliance action against these firms.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.